Research Progress of Allogeneic Hematopoietic Stem Sell Trans-plantation in the Treatment of Adult Hemophagocytic Lympho-histiocytosis --Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 301-305, 2023.
Article
en Zh
| WPRIM
| ID: wpr-971141
Biblioteca responsable:
WPRO
ABSTRACT
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory clinical syndrome of uncontrolled immune response which results in hypercytokinemia due to underlying primary or secondary immune defect. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only cure therapy for primary HLH and recurrent/refractory hemophagocytic lymphohistiocytosis. Compared with children HLH, adult HLH is a much more heterogeneous syndrome requiring a more individualized protocol depending on the underlying trigger, disease severity and genetic background. At present, there remain controversies in various aspects including indications of haematopoietic cell transplantation (HCT), conditioning regimen, efficacy and prognosis. This article will review the recent advances of allo-HSCT in the treatment of adult HLH based on the above issues.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Trasplante de Células Madre Hematopoyéticas
/
Acondicionamiento Pretrasplante
/
Linfohistiocitosis Hemofagocítica
Límite:
Adult
/
Child
/
Humans
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Año:
2023
Tipo del documento:
Article